ArticleFrontiers in pharmacology2026
Mechanistic elucidation of Wuling Powder targeting macrophage polarization to ameliorate renal ischemia-reperfusion injury via multidimensional computational systems pharmacology coupled with experimental validation.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The blurry mechanism of Wuling Powder (WLP) in treating renal ischemia-reperfusion injury (R-IRI) has greatly hindered its clinical promotion and application as well as the development of modern preparations. This study applied computational systems pharmacology combined with experimental validation to reveal the mechanism of Wuling Powder (WLP) in ameliorating renal ischemia reperfusion injury (R-IRI) by regulating macrophage polarization (MP). Methods: Firstly, the core target mechanism of WLP in treating R-IRI by regulating MP was clearly identified through using multidimensional AI computational systems pharmacology, including network pharmacology, the Gene Expression Omnibus database analysis, machine learning, molecular docking etc. Results: As a result, the core target of WLP in improving MP for treating R-IRI was confirmed to be PLAUR, HSPA1A, and FOS. Then, molecular dynamics simulation revealed that the 3,4-Dihydroxybenzaldehyde-PLAUR complex, which exhibited the least negative docking score, could still bind stably. On this basis, in vivo experiments combined with multivariate statistics and correlation analysis further demonstrated that WLP and its main active compound 3,4-Dihydroxybenzaldehyde could significantly modulate MP by regulating PLAUR to improve R-IRI. Discussion: These findings collectively support PLAUR, HSPA1A, and FOS as core therapeutic targets through which WLP modulates MP to alleviate R-IRI. This systematic research provides a solid theoretical basis for the clinical application and modern drug development of WLP in the prevention and treatment of R-IRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.